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Dilated cardiomyopathy (DCM) is a leading cause of cardiac death in children. Approximately 30% of children die 
or need cardiac transplantation in the first year after diagnosis. We established a protocol to improve the outcome 
in this high-risk population. 
Patients and methods 
We present our experience in 21 patients (mean age 8 month, mean weight 6 kg) treated in our institution from 
2006 to 2015. The patients were diagnosed with DCM with a highly impaired function of the LV (mean EF 17%) 
and a conserved function of the RV (mean EF 52%). Our protocol for medical enhancement of left ventricular 
recovery in association with pulmonary artery banding involves the use of a highly specific β1-blocker, an 
angiotensin-converting enzyme inhibitor and an aldosterone antagonist. Our therapy aims to reduce oxygen 
consumption and improve oxygen delivery. Heart rate control is the most important goal; therefore clonidine is 
given after surgical procedure and digoxin in long-term treatment if heart rate remains high despite adequate 
β1-blocker therapy. To improve oxygen delivery our goal is to archive haemoglobin levels of 12-14 g/dl, therefore 
Erythropoietin is given as long term treatment. Additional treatments include supplementation of carnitine, 
coenzyme Q, riboflavin or thiamine. 
Results 
At a mean follow up of 36 month (range 2-120) freedom from death was 91% and freedom from heart 
transplantation was 85%. Surviving patients showed a significant improvement in left ventricular ejection fraction 
(from 17 ± 6 to 50 ± 11%) and LVEdD (z-score from +7 ± 2 to +1.7 ± 1.9). The levels of BNP improved 
significantly (from 3222 ± 2756 to 70 ± 56 pg/ml). 
Conclusion 
Our data suggest that the medical and surgical approach described may result in a markedly improved 
medium-term outcome in children with DCM. Further studies are required to evaluate the long-term-outcome of 
these patients. 
